Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

AC Immune identifies new MAPT aggregation inhibitors

Sep. 16, 2020

RNA-targeted CRISPR reverses myotonic dystrophy symptoms

Sep. 16, 2020

Specific PAC1 receptor antibody as potential new treatment of primary headaches

Sep. 16, 2020

Preliminary results support ongoing development of Biogen's BTK inhibitor

Sep. 16, 2020

LB reports first-in-human data with amisulpride derivative LB-102

Sep. 15, 2020

Cassava reports final phase IIb study results with sumifilam in Alzheimer's disease

Sep. 15, 2020

Immunity Pharma reports interim data from phase I/IIa study of IPL-344 in ALS

Sep. 15, 2020

GlyT1 inhibitor BI-425809 to improve cognition impairment in schizophrenia

Sep. 15, 2020

SanBio reports new phase IIb analyses for SB-623 in chronic motor deficit from ischemic stroke

Sep. 14, 2020

Pentamidine targets S100B to improve experimental multiple sclerosis

Sep. 14, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 21, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 19, 2026
‘Detargeted’ targeted gene therapy improves activity in Pompe
BioWorld
A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...
WHO declares Ebola outbreak a public health emergency of international concern
BioWorld
The threat posed by the Ebola outbreak in the Democratic Republic of Congo has intensified, with the confirmation that it is caused by the Bundibugyo species of...
Nxera Pharma prepares and tests new GPR17 antagonists
BioWorld Science
Nxera Pharma UK Ltd. has identified new uracil nucleotide/cysteinyl leukotriene receptor (GPR17; P2Y-Like) antagonists potentially useful for the treatment of...